Brendan Mee is a Partner in the Patents Group at Pearl Cohen’s New York office. A Chemical Engineer and former Patent Examiner at the U.S. Patent and Trademark Office (USPTO), Brendan specializes in IP prosecution, strategy and portfolio management. He proactively seeks to identify opportunities for clients to maximize the value of their intellectual property.
Brendan has deep experience prosecuting Trademark, Design and Utility Patent portfolios in the United States and around the world and strives to tailor each portfolio to the needs of individual clients. His client-counseling expertise includes evaluating patentability and freedom to operate in different technological and market environments and providing thoughtful invalidity and non-infringement opinions to guide clients’ licensing and other business strategy decisions. In addition to drafting and successfully prosecuting patents globally, Brendan has successfully prosecuted appeals at the USPTO Patent Trial and Appeal Board (PTAB) and participated in patent litigation before the International Trade Commission (ITC) on behalf of the firm’s clients.
A graduate of Columbia University, Brendan has core technological competence in the mechanical and chemical areas. He has worked with individual inventors, small entities and Fortune 500 companies in the life sciences, medical devices, industrial chemicals, and textiles fields, among many others.
Brendan is a thought leader, having taught the CLE program, Introduction to Copyright, Trademark, and Other Intellectual Property Law at the New York City Bar Association (2012). He maintains an ongoing contribution to Lexis Practice Advisor® on Lost Profits in Patent Litigation. Brendan is a member of the American Chemical Society and the New York Intellectual Property Law Association (NYIPLA) and participated in preparing NYIPLA’s brief Amicus Curiae in Support of Petitioner, Merck KGaA v. Integra LifeSciences, No. 2003-1237 (2005) submitted to the Supreme Court.